Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: xeneticbio.com
8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
10-Q - Xenetic Biosciences, Inc. (0001534525) (Filer)
8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
EFFECT - Xenetic Biosciences, Inc. (0001534525) (Filer)
8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
DEFA14A - Xenetic Biosciences, Inc. (0001534525) (Filer)
DEF 14A - Xenetic Biosciences, Inc. (0001534525) (Filer)
S-3 - Xenetic Biosciences, Inc. (0001534525) (Filer)
8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
10-Q - Xenetic Biosciences, Inc. (0001534525) (Filer)
4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
3 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
Transaction with CLS Therapeutics for DNase platform includes two pre-clinical development programs and creates near-term clinical development opportunityDNase based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indicationsXenetic plans to conduct a Phase 1 clinical study of lead asset in locally advanced or metastatic solid tumorsCompany to host update conference call and webcast today, April 27th at 8:30 AM ETFRAMINGHAM, MA / ACCESSWIRE / April 27, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatm
Data presented at the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in CancerResults bolster Company's rationale for incorporating DNase I as an adjunctive treatment to improve therapeutic responses in patients undergoing CAR T cell therapy FRAMINGHAM, MA / ACCESSWIRE / November 21, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease I (DNase I) with chimeric ant
Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indicationsOngoing progress towards first in human clinical study for locally advanced or metastatic solid tumorsStrategic focus on exploratory investigator-initiated studies with institutional partnersEnded the quarter with $6.8 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / November 13, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the third quarter of
Data presented at Society for Immunotherapy of Cancer (SITC) 2024Systemic DNase I combined with
Company is advancing DNase-based oncology program towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / November 7, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has extended its previously announced Research Funding and Option Agreement (the "Agreement") with The Scripps Research Institute ("TSRI") to advance the development of the Company's program on the combination of systemic DNase and CAR T-cell therapies. Xenetic's systemic DNase I candidate is undergoing precl
FRAMINGHAM, MA / ACCESSWIRE / October 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024, in Houston, Texas and virtually.Details of the presentation are as follows:Title: DNase I Targeting of Neutrophil Extracellular Traps Improves CTLA-4 Immune Checkpoint blockade in Models of MSS/MMRp CRCAbstract Number: 765Presenter: Reid Bissonnette, Ph.D., Executive Cons
Xenetic to supply recombinant DNase I to Tokyo Medical University for evaluation as a treatment of Ewing sarcoma in unique preclinical model FRAMINGHAM, MA / ACCESSWIRE / October 17, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has entered into a Materials Transfer Agreement with Tokyo Medical University to advance the development of its systemic DNase program.Under the terms of the agreement, Professor Takuro Nakamura of the Department of Experimental Pathology, Institute of Medical Science at Tokyo Medical
Ongoing preclinical studies with data expected before year endFocus on demonstration of DNase-based oncology program in clinical proof-of-concept studies in multiple indicationsEnded the quarter with $7.3 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / August 14, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the second quarter of 2024. "We remain confident in the potential of our DNase-based oncology platform and continue to advance our preclinical studies with data expected before
Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced the appointment of James Parslow, the Company's Chief Financial Officer, as interim Chief Executive Officer, effective May 16, 2024."I am a strong believer in the potential of our innovative immune-oncology technologies addressing hard-to-treat cancers. This management change will allow us to focus our resources on driving our pipeline toward
Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumorsEnded the quarter with $7.8 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / May 10, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the first quarter of 2024 and provided a business update."We have initiated several
- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platformFRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has entered into a Research Funding Agreement and a Material Transfer Agreement with the University of Virginia ("UVA") to advance the development of its systemic DNase program. Xenetic's DNase-based oncology platform is designed to target neutrophil extracellular traps ("NETs"), which are weblike structures co
Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced the appointment of James Parslow, the Company's Chief Financial Officer, as interim Chief Executive Officer, effective May 16, 2024."I am a strong believer in the potential of our innovative immune-oncology technologies addressing hard-to-treat cancers. This management change will allow us to focus our resources on driving our pipeline toward
Dr. Bissonnette brings over 25 years in small molecule and biotherapeutic drug discovery and development, oncology and inflammation research and regulatory expertiseFRAMINGHAM, MA / ACCESSWIRE / May 4, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has engaged Reid P. Bissonnette, Ph.D. to serve as an executive consultant for translational research and development and to support the advancement of the Company's DNase-based oncology platform. Xenetic's DNase-based oncology platform is designed to target neutrophil extrace
Mr. Cullison brings over 20 years of experience in the pharmaceutical industry with a broad range of expertise across business development and strategic planningFRAMINGHAM, MA / ACCESSWIRE / May 3, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has engaged Scott N. Cullison to serve as an executive consultant for business development and to support the advancement of the Company's DNase-based oncology platform. Mr. Cullison brings over 20 years of experience in the pharmaceutical industry. He has amassed a broad range
Appointment of Dr. Spicer to Scientific Advisory Board bolsters expertise in Neutrophil Extracellular Traps ("NETs") in cancer biology and provides valuable assistance in advancing development of the Company's DNase platformFRAMINGHAM, MA / ACCESSWIRE / November 16, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced the appointment of Jonathan Spicer, MD, PhD to its Scientific Advisory Board ("SAB").Dr. Spicer is recognized as a leader in understanding how neutrophils impact cancer progression, in particular, the rol
FRAMINGHAM, MA / ACCESSWIRE / October 4, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced the appointment of Allan Tsung, MD to its Scientific Advisory Board.Dr. Tsung is a nationally and internationally recognized leader specializing in evaluating and caring for patients with liver, bile duct and pancreas cancers and is an expert in laparoscopic and robotic surgery. He currently serves as Chair of the Department of Surgery at the University of Virginia ("UVA") School of Medicine and Director of the Cancer Therapeutics program
SC 13D/A - Xenetic Biosciences, Inc. (0001534525) (Subject)
SC 13D/A - Xenetic Biosciences, Inc. (0001534525) (Subject)
SC 13D - Xenetic Biosciences, Inc. (0001534525) (Subject)
SC 13G - Xenetic Biosciences, Inc. (0001534525) (Subject)
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(0.79) by 1.27 percent. The company reported quarterly sales of $510.817 thousand which missed the analyst consensus estimate of $650.000 thousand by 21.41 percent. This is a 15.69 percent decrease over sales of $605.844 thousand the same period last year.
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.87) by 11.49 percent. This is a 23 percent increase over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $671.96 thousand which missed the analyst consensus estimate of $680.00 thousand by 1.18 percent. This is a 37.99 percent increase over sales of $486.97 thousand the same period last year.
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly earnings of $0.77 per share which beat the analyst consensus estimate of $(0.87) by 188.51 percent. This is a 177 percent increase over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $671.96 thousand which missed the analyst consensus estimate of $680.00 thousand by 1.18 percent. This is a 37.99 percent increase over sales of $486.97 thousand the same period last year.
- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platform
Gainers PHAXIAM Therapeutics (NASDAQ:PHXM) shares moved upwards by 22.1% to $5.13 during Tuesday's regular session. The market value of their outstanding shares is at $31.1 million. Travere Therapeutics (NASDAQ:TVTX) stock moved upwards by 20.66% to $7.59. The market value of their outstanding shares is at $570.3 million. MSP Recovery (NASDAQ:LIFW) stock rose 18.99% to $4.0. The market value of their outstanding shares is at $57.2 million. Xenetic Biosciences (NASDAQ:XBIO) stock rose 17.84% to $4.16. The company's market cap stands at $6.4 million. Cerevel Therapeutics Hldg (NASDAQ:CERE) shares moved upwards by 16.28% to $36.98. The company's market cap stands at $6.6 billion. Kala Bio
Xenetic Biosciences (NASDAQ:XBIO) reported its Q3 earnings results on Friday, November 10, 2023 at 08:35 AM. Here's what investors need to know about the announcement. Earnings Xenetic Biosciences beat estimated earnings by 38.39%, reporting an EPS of $-0.69 versus an estimate of $-1.12. Revenue was up $196 thousand from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.44 which was followed by a 0.83% increase in the share price the next day. To track all earnings releases for Xenetic Biosciences visit their earnings calendar here. This article was generated by Benzinga's automated content engine and reviewed by an editor.
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(1.12) by 38.39 percent. This is a 15 percent decrease over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $611.17 thousand which beat the analyst consensus estimate of $460.00 thousand by 32.86 percent. This is a 47.54 percent increase over sales of $414.25 thousand the same period last year.
Gainers Evelo Biosciences (NASDAQ:EVLO) stock increased by 60.7% to $0.19 during Tuesday's pre-market session. The company's market cap stands at $21.6 million. DICE Therapeutics (NASDAQ:DICE) shares moved upwards by 38.07% to $46.74. The market value of their outstanding shares is at $2.2 billion. Nuwellis (NASDAQ:NUWE) stock moved upwards by 34.81% to $3.95. The company's market cap stands at $4.7 million. Biofrontera (NASDAQ:BFRI) shares increased by 29.54% to $0.57. The company's market cap stands at $15.2 million. Innovative Eyewear (NASDAQ:LUCY) shares increased by 25.11% to $2.74. The market value of their outstanding shares is at $23.0 million. Cano Health (NYSE:CANO) stock inc
HC Wainwright has downgraded Xenetic Biosciences Inc (NASDAQ:XBIO) from Buy to Neutral, citing pending clinical path visibility. In the Q1 earnings release, the company announced continued progress with the DNase-based oncology program toward Phase 1 study for pancreatic carcinoma and other locally advanced or metastatic solid tumors. Xenetic announced a one-for-ten reverse stock split, the second reverse split in four years. The analyst noted that the split is not necessarily concerning amid this volatile healthcare market. But the analyst is moving to the sidelines due to volatile markets combined with a lack of catalysts to shore up the shares. The analyst has downgraded based on th